Clinical Trial Update: TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy [Phase 2]

View source ↗

Summary

Phase 2 trial update of TAGRISSO (osimertinib) in NSCLC patients with T790M mutations detected by liquid biopsy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Asan Medical Center | Conditions: NSCLC | Phase 2 | Status: COMPLETED